To evaluate the clinical characteristics and treatment efficacy of patients with severe primary IGF-1 deficiency (PSIGFD) using a recombinant IGF-1 (rhIGF-1). The gene discussed is IGF1; the disease is growth delay due to insulin-like growth factor type 1 deficiency.